These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26093818)

  • 21. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of HER2-positive Circulating Tumor Cells Using the LiquidBiopsy System in Breast Cancer.
    Chen W; Zhang J; Huang L; Chen L; Zhou Y; Tang D; Xie Y; Wang H; Huang C
    Clin Breast Cancer; 2019 Feb; 19(1):e239-e246. PubMed ID: 30472074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
    Wang Y; Kim TH; Fouladdel S; Zhang Z; Soni P; Qin A; Zhao L; Azizi E; Lawrence TS; Ramnath N; Cuneo KC; Nagrath S
    Sci Rep; 2019 Jan; 9(1):566. PubMed ID: 30679441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
    Dhar M; Wong J; Che J; Matsumoto M; Grogan T; Elashoff D; Garon EB; Goldman JW; Sollier Christen E; Di Carlo D; Kulkarni RP
    Sci Rep; 2018 Feb; 8(1):2592. PubMed ID: 29416054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
    Khattak MA; Reid A; Freeman J; Pereira M; McEvoy A; Lo J; Frank MH; Meniawy T; Didan A; Spencer I; Amanuel B; Millward M; Ziman M; Gray E
    Oncologist; 2020 Mar; 25(3):e520-e527. PubMed ID: 32162809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
    Wang W; Zhang T
    Future Oncol; 2021 May; 17(13):1625-1635. PubMed ID: 33726500
    [No Abstract]   [Full Text] [Related]  

  • 30. Androgen receptor expression on circulating tumor cells in metastatic breast cancer.
    Fujii T; Reuben JM; Huo L; Espinosa Fernandez JR; Gong Y; Krupa R; Suraneni MV; Graf RP; Lee J; Greene S; Rodriguez A; Dugan L; Louw J; Lim B; Barcenas CH; Marx AN; Tripathy D; Wang Y; Landers M; Dittamore R; Ueno NT
    PLoS One; 2017; 12(9):e0185231. PubMed ID: 28957377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of circulating tumor cells in metastatic breast cancer patients.
    Sanislo L; Vertakova-Krakovska B; Kuliffay P; Brtko J; Galbava A; Galbavy S
    Endocr Regul; 2011 Jul; 45(3):113-24. PubMed ID: 21793623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased levels of circulating cytokines VEGF, TNF-β and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients.
    Cierna Z; Smolkova B; Cholujova D; Gronesova P; Miklikova S; Cihova M; Plava J; Mego M
    Sci Rep; 2021 Jan; 11(1):1294. PubMed ID: 33446741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
    Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
    PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
    Tamminga M; de Wit S; Hiltermann TJN; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    J Immunother Cancer; 2019 Jul; 7(1):173. PubMed ID: 31291995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 expressing circulating tumour cells in head and neck cancers.
    Kulasinghe A; Perry C; Kenny L; Warkiani ME; Nelson C; Punyadeera C
    BMC Cancer; 2017 May; 17(1):333. PubMed ID: 28511705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
    Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.